Evidence map›Paper›PMID 25596746›Full record

ArticleOncotarget2015

Peritoneal expression of Matrilysin helps identify early post-operative recurrence of colorectal cancer.

Giuseppe S Sica, Cristina Fiorani, Carmine Stolfi, Giovanni Monteleone, Eleonora Candi, Ivano Amelio, Valeria Catani, Simone Sibio, Andrea Divizia, Giorgia Tema and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Giuseppe S SicaDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Cristina FioraniDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Carmine StolfiDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Giovanni MonteleoneDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Eleonora CandiDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Ivano AmelioMedical Research Council, Toxicology Unit, Leicester, UK.
Valeria CataniDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Simone SibioDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Andrea DiviziaDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Giorgia TemaDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Edoardo IaculliDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Achille L GaspariDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
University of Rome Tor Vergata · ITMedical Research Council · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recurrence of colorectal cancer (CRC) following a potentially curative resection is a challenging clinical problem. Matrix metalloproteinase-7 (MMP-7) is over-expressed by CRC cells and supposed to play a major role in CRC cell diffusion and metastasis. MMP-7 RNA expression was assessed by real-time PCR using specific primers in peritoneal washing fluid obtained during surgical procedure. After surgery, patients underwent a regular follow up for assessing recurrence. transcripts for MMP-7 were detected in 31/57 samples (54%). Patients were followed-up (range 20-48 months) for recurrence prevention. Recurrence was diagnosed in 6 out of 55 patients (11%) and two patients eventually died because of this. Notably, all the six patients who had relapsed were positive for MMP-7. Sensitivity and specificity of the test were 100% and 49% respectively. Data from patients have also been corroborated by computational approaches. Public available coloncarcinoma datasets have been employed to confirm MMP7 clinical impact on the disease. Interestingly, MMP-7 expression appeared correlated to Tgfb-1, and correlation of the two factors represented a poor prognostic factor. This study proposes positivity of MMP-7 in peritoneal cavity as a novel biomarker for predicting disease recurrence in patients with CRC.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorColorectal NeoplasmsFemaleHumansMaleMatrix Metalloproteinase 7Middle AgedNeoplasm Recurrence, LocalPeritoneumPostoperative PeriodPrognosisBiomarkers, TumorMatrix Metalloproteinase 7MMP7 protein, humancolorectal carcinomaMMP7

Identifiers

PMID25596746
PMCPMC4537023
OpenAlexW1887769232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.